Skip to main content
OpenTrials
Completed

NCT Number: NCT00531908

Physiopathology of Sodium Retention in Acromegaly

Acromegaly is a disease due to an excess of growth hormone that abnormally occurs in adulthood. It is due to a benign (non cancerous) tumor located in a particular part of the brain that secretes several hormones, the hypophysis. The excess of growth hormones in adults induces an increase in bone (resulting in large enlargement of extremities), and organs. The disease is complicated by the apparition of cardiovascular events including retention of water, salt in the tissues and increase in blood pressure, that altogether might major the mortality of the patients. The investigators recently got experimental data suggesting that the retention of water and salt is mainly due to the activation by the growth hormone of a renal transporter of sodium. Because this transporter is highly sensitive to amiloride, a well know diuretic, the investigators hypothesize that this drug will be very efficient in treating the hypertension in patients, as compared to another diuretic, furosemide.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acromegaly Bone Diseases Bone Diseases, Endocrine Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Endocrine System Diseases Hyperpituitarism Hypertension Hypothalamic Diseases Musculoskeletal Diseases Nervous System Diseases Pituitary Diseases Vascular Diseases

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hopital Bicetre

Paris, 75000, France

About this study

To prove this, we compared the response to amiloride administrated before and after treatment of acromegaly in the same subject. We will also compare the response to furosemide administrated before and after treatment of acromegaly in the same subject. We expected that the response to amiloride will be greater before than after treatment, while the response to furosemide will be lesser before than after treatment.

Detailed Description:

Definition: Extended description of the protocol, including information not already contained in other fields, such as comparison(s) studied.

Patients will be recruited in the Department of Endocrinology and Reproductive diseases in BICETRE University Hospital and will be explored in the Centre for Clinical Investigation of HEGP. Investigations will be performed during 4 separate day-hospital stays (2 pre-treatment and 2 post treatment) in the CIC of HEGP. The tests will consist of blood and urine sample collections before and after a single dose administration of furosemide or amiloride. The tests will be performed before treatment of acromegaly in random order and separated by 48hours, interval performed before treatment, and repeated in the same order after normalization of IGF1 by appropriate treatment.

The study will last for 2 years, with a 12 months maximal participation of each patient

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 18 to 75 yrs
  • proven evolutive acromegalia with indication of treatment (surgical or medical)
  • controlled blood pressure (systolic BP < 140 mmHg et diastolic BP < 90 mmHg)
  • signed informed consent
  • efficient contraception in women

Exclusion criteria

  • edematous state unrelated to acromegaly
  • history of sulfamide intolerance
  • hemoglobin < 8g/dL
  • pregnant or breastfeeding women
  • inability to give informed consent
  • blood donation in the preceding 3 months

Treatment and study plan

Furosemide

Drug

furosemide

Primary outcomes

  1. To compare natriuretic effect of a single dose administration of amiloride (20 mg) in patients with acromegaly

    Time frame: before and after treatment of acromegaly.

Secondary outcomes

  1. To compare natriuretic effect of a single dose of furosemide (bolus 5 mg, then 10 mg over 2 hrs) in patients with acromegaly

    Time frame: before and after treatment of acromegaly.

  2. To study the difference of the intranasal potential

    Time frame: before and after treatment of acromegaly.

Sponsors and collaborators

Lead sponsor

Assistance Publique - Hôpitaux de Paris

Other

Collaborators

  • Institut National de la Santé Et de la Recherche Médicale, France

Registry information

Acronym: AcromEnaC

Important dates

Study start
2007
Primary completion
2009
Study completion
2009
First posted
Sep 19, 2007
Registry last updated
Dec 7, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.